ORION Biotech Catalyst Calendar
Menu

Free biotech catalyst calendar

Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.

All stages · All sizes · All periods

Filters

Stage
Event type
Company size (public float)
Period

Optional; keeps the company’s stated period precision.

250 programs as of

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

Window ends in: H2 2026

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. TNGXTango Therapeutics · TNG456Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    from this trial in the second half of 2026.Details

    Tango Therapeutics, Inc. (TNGX) · TNG456

    Stage: Not stated

    Public float (as of ): $528M (SEC filing) · $500M–$2B

    Period the company stated: second half of 2026

    We anticipate providing initial clinical data from this trial in the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-343424 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “Release initial TNG456 glioblastoma data 2H 2026” · SEC filing
    2. · “We anticipate providing initial clinical data from this trial in 2026.” · SEC filing
  2. VIRVir Biotechnology · VIR-5818Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    with pembrolizumab, in the second half of 2026.Details

    Vir Biotechnology, Inc. (VIR) · VIR-5818

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $689M (SEC filing) · $500M–$2B

    Period the company stated: second half of 2026

    The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.

    SEC Form 8-K · Filed: · Accession: 0001628280-26-053351 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” · SEC filing
    2. · “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” · SEC filing
    3. · “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” · SEC filing
  3. VRDNViridian Therapeutics · VRDN-008Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H 2026

    volunteer data expected in 2H 2026Details

    Viridian Therapeutics, Inc.\DE (VRDN) · VRDN-008

    Stage: Phase 1SEC filing · “phase 1”

    Public float (as of ): $943M (SEC filing) · $500M–$2B

    Period the company stated: 2H 2026

    VRDN-008: phase 1 healthy volunteer data expected in 2H 2026

    SEC Form 8-K · Filed: · Accession: 0001193125-26-336691 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “We expect healthy volunteer data in the second half of 2026.” · SEC filing
    2. · “healthy volunteer data available in 2026.” · SEC filing
  4. VRTXVertex Pharmaceuticals · VX-670Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    and share results in the second half of 2026.Details

    VERTEX PHARMACEUTICALS INC / MA (VRTX) · VX-670

    Stage: Not stated

    Public float (as of ): $113.4B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    Vertex is on track to complete dosing in the trial and share results in the second half of 2026.

    SEC Form 8-K · Filed: · Accession: 0000875320-26-000256 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Vertex is on track to complete enrollment and dosing in the trial and share results in the second half of 2026.” · SEC filing
  5. VRTXVertex Pharmaceuticals · VX-828Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    to share results in the second half of 2026.Details

    VERTEX PHARMACEUTICALS INC / MA (VRTX) · VX-828

    Stage: Not stated

    Public float (as of ): $113.4B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    Vertex completed dosing in this study and is on track to share results in the second half of 2026.

    SEC Form 8-K · Filed: · Accession: 0000875320-26-000256 · Last checked: · Matched

  6. WVEWave Life Sciences · WVE-006Topline/data readout MatchedSEC ↗Watch

    Period the company stated: the second half of 2026

    of RestorAATion-2 in the second half of 2026.Details

    Wave Life Sciences, Inc. (WVE) · WVE-006

    Stage: Not stated

    Public float (as of ): $851M (SEC filing) · $500M–$2B

    Period the company stated: the second half of 2026

    We expect to share data from the 600 mg monthly multidose cohort of RestorAATion-2 in the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-324949 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “Wave expects to share data from the 600 mg (monthly) multidose cohort in the second half of 2026.” · SEC filing
    2. · “We also expect to share data from the 600 mg multidose cohort in the second half of 2026.” · SEC filing
    3. · “Wave also expects to share data from the 600 mg multidose cohort in the second half of 2026.” · SEC filing
  7. WVEWave Life Sciences · WVE-007Topline/data readout MatchedSEC ↗Watch

    Period the company stated: the second half of 2026

    cohort, are expected in the second half of 2026.Details

    Wave Life Sciences, Inc. (WVE) · WVE-007

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $851M (SEC filing) · $500M–$2B

    Period the company stated: the second half of 2026

    Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-324949 · Last checked: · Matched

  8. ZYMEZymeworks · pasritamig + JNJ-9401Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    of therapy, during the second half of 2026.Details

    Zymeworks Inc. (ZYME) · pasritamig + JNJ-9401

    Stage: Not stated

    Public float (as of ): $649M (SEC filing) · $500M–$2B

    Period the company stated: second half of 2026

    in combination with JNJ-9401 in patients with advanced prostate cancer who have progressed after multiple lines of therapy, during the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001937653-26-000047 · Last checked: · Matched

Window ends in: H1 2027

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. TGTXTG Therapeutics · ublituximab subcutaneousTopline/data readout MatchedSEC ↗Watch

    Period the company stated: year-end 2026 or early 2027

    Phase 3 data is expected year-end 2026 or early 2027Details

    TG THERAPEUTICS, INC. (TGTX) · ublituximab subcutaneous

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $2.5B (SEC filing) · Over $2B

    Period the company stated: year-end 2026 or early 2027

    Top-line Phase 3 data is expected year-end 2026 or early 2027

    SEC Form 8-K · Filed: · Accession: 0001437749-26-025304 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Top-line Phase 3 data expected year-end 2026 or early 2027” · SEC filing
  2. ANROAlto Neuroscience · ALTO-300Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H 2027

    1H 2027 — ALTO-300 Phase 2b MDD trial topline dataDetails

    Alto Neuroscience, Inc. (ANRO) · ALTO-300

    Stage: Phase 2SEC filing · “Phase 2b”

    Public float (as of ): $55M (SEC filing) · Under $500M

    Period the company stated: 1H 2027

    1H 2027 — ALTO-300 Phase 2b MDD trial topline data

    SEC Form 8-K · Filed: · Accession: 0001999480-26-000022 · Last checked: · Matched

    Earlier SEC statements (5)
    1. · “We expect to report topline data from this trial in mid-2026.” · SEC filing
    2. · “We expect to report topline data from this trial in mid-2026.” · SEC filing
    3. · “We expect to report topline data from this trial in mid-2026.” · SEC filing
    4. · “We expect to report topline data from this trial in mid-2026.” · SEC filing
    5. · “We expect to report topline data from this trial in mid-2026.” · SEC filing
  3. ATOSAtossa Therapeutics · (Z)-endoxifen + goserelinTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H27

    Ph2 data anticipated in 1H27Details

    ATOSSA THERAPEUTICS, INC. (ATOS) · (Z)-endoxifen + goserelin

    Stage: Not stated

    Public float (as of ): $107M (SEC filing) · Under $500M

    Period the company stated: 1H27

    Final Ph2 data anticipated in 1H27

    SEC Form 8-K · Filed: · Accession: 0001193125-26-395694 · Last checked: · Matched

  4. CTMXCytomX Therapeutics · varsetatug masetecan + bevacizumabTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H 2027

    data is anticipated in 1H 2027.Details

    CytomX Therapeutics, Inc. (CTMX) · varsetatug masetecan + bevacizumab

    Stage: Not stated

    Public float (as of ): $372M (SEC filing) · Under $500M

    Period the company stated: 1H 2027

    Initial clinical data is anticipated in 1H 2027.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-338009 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Initial clinical data are anticipated by 1H 2027.” · SEC filing
  5. DNLIDenali Therapeutics · DNL628Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H 2027

    data from this study in 1H 2027.Details

    Denali Therapeutics Inc. (DNLI) · DNL628

    Stage: Not stated

    Public float (as of ): $1.1B (SEC filing) · $500M–$2B

    Period the company stated: 1H 2027

    Denali expects data from this study in 1H 2027.

    SEC Form 8-K · Filed: · Accession: 0001714899-26-000062 · Last checked: · Matched

  6. ERASErasca · ERAS-0015Topline/data readout MatchedSEC ↗Watch

    Period the company stated: H1 2027

    data expected in H1 2027Details

    Erasca, Inc. (ERAS) · ERAS-0015

    Stage: Not stated

    Public float (as of ): $316M (SEC filing) · Under $500M

    Period the company stated: H1 2027

    Additional ERAS-0015 monotherapy and combination data expected in H1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-344584 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “In addition, we anticipate the initiation of monotherapy expansion cohorts and combination dose escalation cohorts as part of the AURORAS-1 trial in the second half of 2026, with associated data readouts planned for 2027.” · SEC filing
  7. GPCRStructure Therapeutics · ACCG-2671Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H 2027

    topline data expected in 1H 2027Details

    Structure Therapeutics Inc. (GPCR) · ACCG-2671

    Stage: OtherSEC filing · “Phase 1/2a”

    Public float (as of ): $834M (SEC filing) · $500M–$2B

    Period the company stated: 1H 2027

    participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

    SEC Form 8-K · Filed: · Accession: 0001104659-26-105688 · Last checked: · Matched

  8. IOVAIovance Biotherapeutics · lifileucelTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H27

    initial data expected in 1H27.Details

    IOVANCE BIOTHERAPEUTICS, INC. (IOVA) · lifileucel

    Stage: Not stated

    Public float (as of ): $534M (SEC filing) · $500M–$2B

    Period the company stated: 1H27

    Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27.

    SEC Form 8-K · Filed: · Accession: 0001104659-26-091619 · Last checked: · Matched

  9. RXRXRecursion Pharmaceuticals · REC-3565Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H27

    data expected in 1H27Details

    RECURSION PHARMACEUTICALS, INC. (RXRX) · REC-3565

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $2.0B (SEC filing) · Over $2B

    Period the company stated: 1H27

    REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27

    SEC Form 10-Q · Filed: · Accession: 0001601830-26-000098 · Last checked: · Matched

    Earlier SEC statements (10)
    1. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    2. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    3. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    4. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    5. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    6. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” · SEC filing
    7. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” · SEC filing
    8. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” · SEC filing
    9. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” · SEC filing
    10. · “REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” · SEC filing
  10. RXRXRecursion Pharmaceuticals · REC-4881Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H27

    clinical data expected in 1H27Details

    RECURSION PHARMACEUTICALS, INC. (RXRX) · REC-4881

    Stage: OtherSEC filing · “Phase 1b/2”

    Public float (as of ): $2.0B (SEC filing) · Over $2B

    Period the company stated: 1H27

    Additional Phase 1b/2 clinical data expected in 1H27

    SEC Form 10-Q · Filed: · Accession: 0001601830-26-000078 · Last checked: · Matched

  11. RXRXRecursion Pharmaceuticals · REC-617Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H27

    data expected in 1H27Details

    RECURSION PHARMACEUTICALS, INC. (RXRX) · REC-617

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $2.0B (SEC filing) · Over $2B

    Period the company stated: 1H27

    REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27

    SEC Form 10-Q · Filed: · Accession: 0001601830-26-000098 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” · SEC filing
    2. · “REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” · SEC filing
    3. · “REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” · SEC filing
    4. · “REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” · SEC filing
  12. STOKStoke Therapeutics · STK-002Topline/data readout MatchedSEC ↗Watch

    Period the company stated: H1 2027

    data anticipated in H1 2027Details

    Stoke Therapeutics, Inc. (STOK) · STK-002

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $592M (SEC filing) · $500M–$2B

    Period the company stated: H1 2027

    Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-330537 · Last checked: · Matched

  13. TSHATaysha Gene Therapies · TSHA-102Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1H 2027

    and regulatory feedback in 1H 2027.Details

    Taysha Gene Therapies, Inc. (TSHA) · TSHA-102

    Stage: Not stated

    Public float (as of ): $544M (SEC filing) · $500M–$2B

    Period the company stated: 1H 2027

    is on track to report topline data and regulatory feedback in 1H 2027.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-344594 · Last checked: · Matched

  14. ZNTLZentalis Pharmaceuticals · azenosertibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: by 1H 2027

    provide a topline readout by 1H 2027.Details

    Zentalis Pharmaceuticals, Inc. (ZNTL) · azenosertib

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $66M (SEC filing) · Under $500M

    Period the company stated: by 1H 2027

    Zentalis expects to complete enrollment in all cohorts of DENALI Part 2 (2a, 2b, 2c) and provide a topline readout by 1H 2027.

    ClinicalTrials.gov NCT05128825 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001725160-26-000061 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “We expect to complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout of the trial by year-end 2026.” · SEC filing
    2. · “Zentalis expects to complete enrollment in all cohorts of DENALI Part 2 (2a, 2b, 2c) and provide a topline readout by year-end 2026.” · SEC filing
    3. · “Zentalis expects to complete enrollment in all cohorts of DENALI Part 2 (2a, 2b, 2c) and provide a topline readout by year-end 2026.” · SEC filing

Window ends in: H2 2027

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. ARGXargenx · efgartigimodTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2027

    3 results expected in the second half of 2027Details

    ARGENX SE (ARGX) · efgartigimod

    Stage: Phase 3SEC filing · “Phase 3”

    Public float: Unknown (no public float found in SEC filings)

    Period the company stated: second half of 2027

    UNITY remains ongoing, with topline Phase 3 results expected in the second half of 2027

    SEC Form 20-F · Filed: · Accession: 0001697862-26-000032 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “UNITY study ongoing in primary Sjögren’s disease; topline results expected in 2027” · SEC filing
  2. ARGXargenx · empasiprubartTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2027

    studies (CIDP) expected in second half of 2027Details

    ARGENX SE (ARGX) · empasiprubart

    Stage: Not stated

    Public float: Unknown (no public float found in SEC filings)

    Period the company stated: second half of 2027

    Topline results from registrational EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027

    SEC Form EX-99.1 · Filed: · Accession: 0001697862-26-000033 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027” · SEC filing
  3. KURAKura Oncology · darlifarnib + cabozantinibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2027

    clinical data in the second half of 2027Details

    Kura Oncology, Inc. (KURA) · darlifarnib + cabozantinib

    Stage: Not stated

    Public float (as of ): $496M (SEC filing) · Under $500M

    Period the company stated: second half of 2027

    initial clinical data in the second half of 2027

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-346884 · Last checked: · Matched

  4. RXRXRecursion Pharmaceuticals · REC-4539Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H27

    data expected in 2H27Details

    RECURSION PHARMACEUTICALS, INC. (RXRX) · REC-4539

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $2.0B (SEC filing) · Over $2B

    Period the company stated: 2H27

    REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27

    SEC Form 10-Q · Filed: · Accession: 0001601830-26-000098 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” · SEC filing
    2. · “REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” · SEC filing
    3. · “REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” · SEC filing
    4. · “REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” · SEC filing
  5. SNDXSyndax Pharmaceuticals · revumenibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2027

    data expected in the second half of 2027Details

    Syndax Pharmaceuticals Inc (SNDX) · revumenib

    Stage: Not stated

    Public float (as of ): $799M (SEC filing) · $500M–$2B

    Period the company stated: second half of 2027

    initial clinical data expected in the second half of 2027

    SEC Form EX-99.1 · Filed: · Accession: 0001193125-26-332736 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Phase 1/2 proof-of-principal trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027” · SEC filing

Window ends in: 2026

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. AUTLAutolus Therapeutics · AUTO8Topline/data readout MatchedSEC ↗Watch

    Period the company stated: end of 2026

    to be reported at the end of 2026.Details

    Autolus Therapeutics plc (AUTL) · AUTO8

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $548M (SEC filing) · $500M–$2B

    Period the company stated: end of 2026

    The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001730463-26-000123 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “initial data from the trial at the end of 2026” · SEC filing
    2. · “initial data is expected to be reported at the end of 2026.” · SEC filing
    3. · “Initial data from the Phase 1 trial are expected to be reported at the end of 2026.” · SEC filing
    4. · “initial data is expected to be reported at the end of 2026.” · SEC filing
  2. BCRXBioCryst Pharmaceuticals · BCX17725Topline/data readout MatchedSEC ↗Watch

    Period the company stated: end of 2026

    data from this part by the end of 2026.Details

    BIOCRYST PHARMACEUTICALS INC (BCRX) · BCX17725

    Stage: Not stated

    Public float (as of ): $1.8B (SEC filing) · $500M–$2B

    Period the company stated: end of 2026

    expects to report data from this part by the end of 2026.

    SEC Form 8-K · Filed: · Accession: 0001171843-26-005223 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “Dosing is ongoing in the Phase 1 Part 4 study in up to 12 patients, with proof-of-concept data expected by year-end 2026.” · SEC filing
    2. · “The company has begun dosing in Part 4 of this trial, which will enroll up to 12 patients for three months, and expects to report data from this part by the end of 2026.” · SEC filing
    3. · “we expect to report data from the clinical trial of BCX17725 for the treatment of Netherton syndrome in up to 12 patients by the end of 2026.” · SEC filing
  3. BEAMBeam Therapeutics · BEAM-301Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 2026

    data from the trial in 2026Details

    Beam Therapeutics Inc. (BEAM) · BEAM-301

    Stage: Not stated

    Public float (as of ): $1.7B (SEC filing) · $500M–$2B

    Period the company stated: 2026

    initial data from the trial in 2026

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-331541 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “BEAM-301 in a Phase 1/2 clinical trial, and expect to report initial clinical data in 2026” · SEC filing
    2. · “data anticipated in 2025” · SEC filing
About this calendar
Calendar

FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.

Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.

How this calendar is made
  • Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
  • Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
  • Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
  • Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
  • Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
  • Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
  • Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
  • Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
  • Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
  • “Wording changed” opens the earlier sentences, each with its date and filing.
  • No forecast, price, score or signal. The calendar repeats what companies wrote.

Want an email when one of these changes? Get a free Watch.

All companies A–Z

A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.A Form 10-K is a company’s annual report to the SEC, with audited financial statements.